Ophthalmology Times

Inside the ASCRS preoperative ocular surface disease algorithm: Key updates

As expectations for refractive cataract surgery continue to rise, preoperative ocular surface optimization remains essential ...
The American Journal of Managed Care

Lotilaner Is Effective, Accessible Method of Treating Demodex Blepharitis

I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis. First of all, making the diagnosis is the seminal event in demodex blepharitis, and it's really ...
Yahoo Finance

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Tallahassee Democrat

FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Seeking Alpha

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment ...
manilatimes

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE)-- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ...